Gsk PLC (GLAXF) — 6-K Filings

6-K Filings (50)

• GSK to Lower Drug Prices, Expand US Access — Dec 23, 2025 Risk: low
  GSK plc announced on December 19, 2025, an agreement with the U.S. government to lower drug prices and expand access to its respiratory medicines for millions o
• GSK plc Buys Back Own Shares — Dec 22, 2025 Risk: low
  GSK plc announced on December 22, 2025, that it has purchased a number of its own ordinary shares. The transactions were executed through its broker, BNP Pariba
• GSK plc Buys Back Own Shares — Dec 19, 2025 Risk: low
  GSK plc announced on December 19, 2025, that it purchased a certain number of its own ordinary shares, each with a nominal value of 31 1/4 pence. The transactio
• GSK plc Buys Back Own Shares — Dec 18, 2025 Risk: low
  GSK plc announced on December 18, 2025, that it repurchased a certain number of its own ordinary shares through its broker, BNP Paribas SA. The filing does not
• 6-K Filing — Dec 17, 2025
• GSK plc Buys Back Own Shares — Dec 16, 2025 Risk: low
  On December 16, 2025, GSK plc announced through its broker, BNP Paribas SA, that it purchased a certain number of its own ordinary shares. The filing does not s
• GSK plc Buys Back Own Shares — Dec 15, 2025 Risk: low
  GSK plc announced on December 15, 2025, that it purchased a number of its own ordinary shares through its broker, BNP Paribas SA. The filing is a report of a fo
• GSK Buys Back Own Shares — Dec 12, 2025 Risk: low
  GSK plc announced on December 12, 2025, that it has purchased a certain number of its own ordinary shares through its broker, BNP Paribas SA. This transaction i
• 6-K Filing — Dec 11, 2025
• GSK'227 Gets FDA Orphan Drug Nod for Lung Cancer — Dec 10, 2025 Risk: low
  On December 10, 2025, GSK plc announced that its investigational drug, GSK'227, received Orphan Drug Designation from the US FDA for the treatment of small-cell
• GSK plc Buys Back Own Shares — Dec 9, 2025 Risk: low
  GSK plc announced on December 9, 2025, that it has purchased a certain number of its own ordinary shares through its broker, BNP Paribas SA. The filing does not
• 6-K Filing — Dec 8, 2025
• GSK plc Buys Back Own Shares — Dec 5, 2025 Risk: low
  GSK plc announced on December 5, 2025, that it has purchased a number of its own ordinary shares, acting through its broker, BNP Paribas SA. The filing does not
• GSK plc Buys Back Own Shares — Dec 4, 2025 Risk: low
  GSK plc announced on December 4, 2025, that it has purchased a number of its own ordinary shares, acting through its broker, BNP Paribas SA. The filing does not
• GSK Buys Back Own Shares Via BNP Paribas — Dec 3, 2025 Risk: low
  GSK plc announced on December 3, 2025, that it purchased a number of its own ordinary shares through its broker, BNP Paribas SA. The filing is a report of a for
• 6-K Filing — Dec 2, 2025
• GSK plc Buys Back Own Shares — Dec 1, 2025 Risk: low
  GSK plc announced on December 1, 2025, that it has purchased a number of its own ordinary shares through its broker, BNP Paribas SA. The filing details a transa
• 6-K Filing — Nov 28, 2025
• 6-K Filing — Nov 26, 2025
• GSK Buys Back Own Shares — Nov 25, 2025 Risk: low
  GSK plc announced on November 25, 2025, that it has purchased a certain number of its own ordinary shares, each with a nominal value of 31 1/4 pence. The transa
• 6-K Filing — Nov 24, 2025
• GSK Buys Back Own Shares — Nov 21, 2025 Risk: low
  GSK plc announced on November 21, 2025, that it purchased a number of its own ordinary shares of 31 pence each through its broker, BNP Paribas SA. This transact
• GSK plc Buys Back Own Shares — Nov 20, 2025 Risk: low
  GSK plc announced on November 20, 2025, that it repurchased a certain number of its ordinary shares through its broker, BNP Paribas SA. The filing details a tra
• 6-K Filing — Nov 19, 2025
• 6-K Filing — Nov 18, 2025
• 6-K Filing — Nov 17, 2025
• GSK Buys Back Own Shares — Nov 14, 2025 Risk: low
  GSK plc announced on November 14, 2025, that it purchased a certain number of its own ordinary shares of 31 1/4 pence each, acting through its broker, BNP Parib
• GSK plc Buys Back Own Shares — Nov 13, 2025 Risk: low
  GSK plc announced on November 13, 2025, that it has purchased a number of its own ordinary shares through its broker, BNP Paribas SA. The filing does not specif
• GSK Buys Back Own Shares — Nov 12, 2025 Risk: low
  GSK plc announced on November 12, 2025, that it has purchased a number of its own ordinary shares, each with a nominal value of 31 1/4 pence. The transactions w
• 6-K Filing — Nov 10, 2025
• 6-K Filing — Nov 7, 2025
• 6-K Filing — Nov 6, 2025
• 6-K Filing — Nov 5, 2025
• GSK plc Buys Back Own Shares — Nov 4, 2025 Risk: low
  GSK plc announced on November 4, 2025, that it has purchased a number of its own ordinary shares through its broker, BNP Paribas SA. The filing details transact
• GSK plc Buys Back Own Shares — Nov 3, 2025 Risk: low
  GSK plc announced on November 3, 2025, that it has purchased a certain number of its own ordinary shares through its broker, BNP Paribas SA. The filing does not
• GSK plc Buys Back Own Shares — Oct 31, 2025 Risk: low
  GSK plc announced on October 31, 2025, that it has purchased a number of its own ordinary shares through its broker, BNP Paribas SA. The filing does not specify
• GSK plc Buys Back Own Shares — Oct 30, 2025 Risk: low
  GSK plc announced on October 30, 2025, that it repurchased a certain number of its own ordinary shares through its broker, BNP Paribas SA. The filing details a
• GSK plc Delivers Strong Q3, Upgrades 2025 Guidance — Oct 29, 2025 Risk: low
  GSK plc reported strong Q3 2025 results, with total sales reaching £8.5 billion. The company has upgraded its full-year 2025 guidance, driven by growth in Speci
• GSK's GSK'227 gets EU Orphan Drug Designation — Oct 28, 2025 Risk: low
  On October 28, 2025, GSK plc announced that its B7-H3-targeted antibody-drug conjugate, GSK'227, received Orphan Drug Designation from the European Union. This
• GSK plc Buys Back Own Shares — Oct 27, 2025 Risk: low
  GSK plc announced on October 27, 2025, that it has purchased a number of its own ordinary shares through its broker, BNP Paribas SA. The filing does not specify
• GSK plc Buys Back Own Shares — Oct 24, 2025 Risk: low
  GSK plc announced on October 24, 2025, that it purchased a number of its own ordinary shares through its broker, BNP Paribas SA. The filing details transactions
• GSK plc Buys Back Own Shares — Oct 23, 2025 Risk: low
  GSK plc announced on October 23, 2025, that it has purchased a number of its own ordinary shares, acting through its broker, BNP Paribas SA. The filing details
• GSK plc Updates on Latozinemab Clinical Trial Results — Oct 22, 2025 Risk: medium
  GSK plc announced on October 21, 2025, that it has provided an update on latozinemab. The company, in partnership with Alector, Inc., confirmed headline results
• GSK's Tebipenem HBr Shows Promise in Phase III for cUTI — Oct 21, 2025 Risk: medium
  GSK plc announced on October 21, 2025, positive Phase III data from its PIVOT-PO study for tebipenem HBr. The study evaluated tebipenem HBr as a potential first
• GSK plc Buys Back Own Shares — Oct 20, 2025 Risk: low
  GSK plc announced on October 20, 2025, that it repurchased a certain number of its own ordinary shares through its broker, BNP Paribas SA. The filing details tr
• GSK plc Buys Back Own Shares — Oct 17, 2025 Risk: low
  GSK plc announced on October 17, 2025, that it repurchased a certain number of its own ordinary shares of 31 1/4 pence each, acting through its broker, BNP Pari
• GSK plc Buys Back Own Shares — Oct 16, 2025 Risk: low
  GSK plc announced on October 16, 2025, that it has purchased a number of its own ordinary shares through its broker, BNP Paribas SA. The filing does not specify
• GSK plc Buys Back Own Shares — Oct 15, 2025 Risk: low
  GSK plc announced on October 15, 2025, that it has purchased a number of its own ordinary shares through its broker, BNP Paribas SA. The filing details transact
• GSK plc Buys Back Own Shares — Oct 14, 2025 Risk: low
  GSK plc announced on October 14, 2025, that it has purchased a number of its own ordinary shares. The transactions were conducted through its broker, BNP Pariba
• GSK plc Buys Back Own Shares — Oct 10, 2025 Risk: low
  GSK plc announced on October 10, 2025, that it repurchased a certain number of its own ordinary shares through its broker, BNP Paribas SA. The filing details a

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX